- Home
- TNXP vs NVCT Comparison
TNXP vs NVCT Comparison
Compare TNXP & NVCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNXP
- NVCT
- Stock Information
- Founded
- TNXP 2007
- NVCT 2020
- Country
- TNXP United States
- NVCT United States
- Employees
- TNXP N/A
- NVCT N/A
- Industry
- TNXP Biotechnology: Pharmaceutical Preparations
- NVCT Medicinal Chemicals and Botanical Products
- Sector
- TNXP Health Care
- NVCT Health Care
- Exchange
- TNXP Nasdaq
- NVCT Nasdaq
- Market Cap
- TNXP 207.5M
- NVCT 184.9M
- IPO Year
- TNXP N/A
- NVCT 2022
- Fundamental
- Price
- TNXP $33.33
- NVCT $8.13
- Analyst Decision
- TNXP Strong Buy
- NVCT Strong Buy
- Analyst Count
- TNXP 2
- NVCT 3
- Target Price
- TNXP $585.00
- NVCT $17.00
- AVG Volume (30 Days)
- TNXP 1.1M
- NVCT 97.5K
- Earning Date
- TNXP 08-15-2025
- NVCT 08-05-2025
- Dividend Yield
- TNXP N/A
- NVCT N/A
- EPS Growth
- TNXP N/A
- NVCT N/A
- EPS
- TNXP N/A
- NVCT N/A
- Revenue
- TNXP $10,041,000.00
- NVCT N/A
- Revenue This Year
- TNXP $11.66
- NVCT N/A
- Revenue Next Year
- TNXP $793.18
- NVCT N/A
- P/E Ratio
- TNXP N/A
- NVCT N/A
- Revenue Growth
- TNXP N/A
- NVCT N/A
- 52 Week Low
- TNXP $6.76
- NVCT $4.44
- 52 Week High
- TNXP $137.25
- NVCT $11.80
- Technical
- Relative Strength Index (RSI)
- TNXP 52.50
- NVCT 37.24
- Support Level
- TNXP $33.41
- NVCT $8.79
- Resistance Level
- TNXP $37.42
- NVCT $9.30
- Average True Range (ATR)
- TNXP 3.48
- NVCT 0.50
- MACD
- TNXP -1.12
- NVCT -0.11
- Stochastic Oscillator
- TNXP 33.66
- NVCT 12.43
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
About NVCT Nuvectis Pharma Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.